• Publications
  • Influence
CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients
TLDR
Analysis of the CDKN2 deletion in 215 adult B- lineage acute lymphoblastic leukemia patients and related cytogenetic prognostic factors revealed that the distribution of CD KN2 deletion is higher in relapse patients than all patients, and had an adverse effect on patients with BCR-ABL fusion gene or with MLL rearrangement. Expand
A comparative proteomic study of Homoharringtonine-induced apoptosis in leukemia K562 cells
TLDR
Hsps, DJ-1 and thioredoxin, which were also shown to decrease in primary cells from imatinib-resistant patients, may be promising potential targets for mechanistic research and new clinical treatments. Expand
Therapeutic immune monitoring of CD4+CD25+ T cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
TLDR
Although treatment with imatinib, dasatinib and nilotinib demonstrated similar inhibitory effects on the quantity of Tregs in vivo, the TKIs exhibited differential effects onThe function of T Regs in vitro, suggesting that personalized treatment and follow-up of CML patients during TKI treatment, particularly for those who received post-transplant TKItreatment may be beneficial. Expand
LOXL2 Highly-Expressed Induce the Transition of Stromal Cells into Cancer-Associated Fibroblasts Which Maybe Involve in Myeloproliferative Neoplasms Progession
TLDR
Higher level of LOXL2 could be promote MPN progression by modulating several functions of surrounding stromal cells which acquire features of cancer-associated fibroblasts involved in the pathogenesis of MPN. Expand
A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients
TLDR
This report reports for the first time a single PV patient who carries concomitant CALR and JAK2V617F mutations and one ET patient carrying the double gene mutations and Interestingly, these two patients had a good response to interferon alfa treatment. Expand
Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia
TLDR
CDKN2 deletion is frequently acquired during Ph-positive ALL progression and serves as a poor prognostic marker of long-term outcome in Ph- positive ALL patients with CD KN2 deletion even after the second-generation tyrosine kinase inhibitor treatment. Expand
MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy
TLDR
The results of the present study showed that dysregulated miR-153-3p may target Bcl-2 to promote the development of IM resistance and attenuate IM-induced apoptosis in CML. Expand
EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins
TLDR
It is illustrated that aberrant activation of EphB4/ephrinB2 may mediate chronic myeloid leukemia resistance involved in cytoskeletal proteins and restore sensitivity to imatinib in vitro and in vivo. Expand
CDKN2 Gene Deletion As Poor Prognosis Predictor Involving in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients
TLDR
Patients with CDKN2 gene deletion were benefited from allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and was a possible poor prognostic marker in long-term outcomes. Expand
Prognostic Significance of Monosomal Karyotype in Adult Patients With Acute Myeloid Leukemia Treated With Risk-Adapted Protocols.
TLDR
HD-Ara-C therapy followed by allo-HSCT could improve the prognosis of MK-positive AML patients and was associated with a lower complete remission rate. Expand
...
1
2
...